Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters’ option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share.
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
Kharabi led development of CD19 CAR-T therapy TECARTUS®; brings extensive cell and gene therapy expertise to guide 3T’s bispecific T-cell engager programs into the clinic
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH)
The SURPASS study is enrolling patients at research sites across the U.S. and Europe
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need
Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)
ROC-101 exhibits favorable pharmacokinetics for once-daily dosing
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients
